Drugs / Vecuronium
Vecuronium
also known as
Vecuronium Bromide · Bromure de vecuronium · Bromuro de vecuronio · Musculax · Norcuron · NSC-759184 · ORG NC 45 · Pancuronium bromide impurity, vecuronium bromide - · +2 more
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | NORCURON | — | 1987-12-29 | fda.gov ↗ |
| Approved | US (FDA) | NORCURON | — | 1984-04-30 | fda.gov ↗ |
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05658692 | Oct 2022 → Oct 2023 | acute respiratory distress syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT02237443 | Aug → Nov 2014 | — | University of Washington | Completed | No outcome recorded |
Also used as a comparator or background therapy in 22 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT07595393 Background | Aug 2026 → Jun 2027 expected | curariform drugs toxicity | Amckaus PTY LTD. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04545424 Background | Jun 2021 → Aug 2026 overdue | adult acute respiratory distress syndrome | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 2 | NCT03376854 Background | May 2018 → Apr 2021 | COVID-19, adult acute respiratory distress syndrome | University of Maryland, Baltimore | Withdrawn | No outcome recorded |
| Phase 2 | NCT00552617 Background | Sep 2005 → Aug 2006 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05444751 Comparator | Mar 2022 → Sep 2026 expected | lumbar disk disease, radiculopathy | Hospital for Special Surgery, New York | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT00473694 Background | Nov 2005 → Nov 2006 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00970762 Comparator | Feb 2003 → Feb 2004 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 412 trials | ||||||
| Phase 4 | NCT03263117 Comparator | Jul 2018 → Apr 2023 | stroke disorder | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT03346070 Background | Jan 2018 → Jan 2019 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT03346057 Background | Dec 2017 → Sep 2019 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT03371953 Comparator | Dec 2017 → Oct 2018 | — | Sir Ganga Ram Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03219294 Comparator | May 2017 → Apr 2018 | arthropathy | Craig Curry | Completed | No outcome recorded |
| Phase 4 | NCT03013075 Background | Nov 2016 → Dec 2017 | — | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 4 | NCT03540030 Comparator | Sep 2016 → Mar 2019 | avascular necrosis, osteoarthritis, rotator cuff syndrome, substance-related disorder | OrthoCarolina Research Institute, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02727712 Background | Apr → Sep 2016 | coronary artery disorder | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 4 | NCT02327923 Comparator | Jan 2015 → Feb 2016 | gallstones | B.P. Koirala Institute of Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02123355 Background | Aug 2014 | CGF1, brain injury | Shaanxi Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02134093 Background | Jul 2014 → May 2015 | — | Tang-Du Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01690338 Comparator | Oct 2012 → Oct 2014 | curariform drugs toxicity | Peking University First Hospital | Unknown | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07557576 Background | May 2024 → Aug 2026 overdue | cleft lip/palate | Iva Smiljanić | Recruiting | No outcome recorded |
| — | NCT02619578 Background | Nov 2013 → Jul 2014 | — | Guizhou Provincial People's Hospital | Completed | No outcome recorded |
| — | NCT01584570 Background | Jan 2012 → Dec 2013 | — | Yonsei University | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vecuronium | “Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium,...” NCT03376854 ↗19“Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium,...” NCT04545424 ↗ “General anesthesia: induction of general anesthesia to facilitate endotracheal intubation: fentanyl (up to 2μg.kg.min-1), propofol (1-2 mg.kg-1), vecuronium (1-2 mg.kg-1).” NCT05444751 ↗ “Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg•h,Vecuronium 0.06\~0.12mg/kg•h” NCT02727712 ↗ “muscle paralysis may be achieved with succinylcholine or non-depolarizing paralytic (rocuronium or vecuronium)” NCT03263117 ↗ “Inj. Vecuronium bromide 0.1mg/kg will be used as muscle relaxant to facilitate tracheal intubation” NCT03013075 ↗ “Dexmedetomidine 0.5 ug/kg + Propofol + Sevoflurane+ Vecuronium” NCT01584570 ↗ |
| Known as | Bromure de vecuronium | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201219 ↗ |
| Known as | Bromuro de vecuronio | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201219 ↗ |
| Known as | Musculax | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201219 ↗ |
| Known as | Norcuron | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201219 ↗ |
| Known as | NSC-759184 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201219 ↗ |
| Known as | ORG NC 45 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201219 ↗ |
| Known as | Pancuronium bromide impurity, vecuronium bromide - | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201219 ↗ |
| Known as | Vecuronium Bromide | “To achieve NMB, participants received steroidal NMBA Rocuronium Bromide or Vecuronium Bromide administered via i.v. infusion and dosed according to participant ABW.” NCT03346070 ↗6“participants received steroidal NMBA Vecuronium Bromide administered via IV infusion and dosed according to participant body weight.” NCT03346057 ↗ “Inj. Vecuronium bromide 0.1mg/kg will be used as muscle relaxant to facilitate tracheal intubation” NCT03013075 ↗ “Vecuronium Bromide for Injection” NCT05658692 ↗ |
| Known as | Vecuronium cation | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201219 ↗ |
| Known as | Vecuronium ion | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201219 ↗ |
| Action | Inhibit | “Neuromuscular blockade (NMB) drugs such as Vecuronium bind to neurotransmitter (acetyl choline) receptors at the neuromuscular junction, blocking their action and producing...” NCT03219294 ↗ |
| Modality | Other / unclassified | “neuromuscular blocking drug (NMBD)” NCT02237443 ↗ |
| Modality | Small molecule | — CHEMBL1201219 ↗ |
| Route | Intravenous | “After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV.” NCT00552617 ↗ |